Funding Opportunity PAR-25-225 from the NIH Guide for Grants and Contracts. Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Funding Opportunity RFA-AI-24-074 from the NIH Guide for Grants and Contracts. The purpose of this notice of funding opportunity (NOFO) is to support multidisciplinary research programs focused on discovery to early development research to inform new approaches to prevent, diagnose, and treat antibiotic-resistant bacterial infections.

Notice NOT-HS-25-008 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-139 from the NIH Guide for Grants and Contracts. Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

Funding Opportunity RFA-DA-26-019 from the NIH Guide for Grants and Contracts. Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips are fast, sensitive, low cost and reasonably accurate. However, as there might not be testing strips for the new threats, the analysis must be performed via sensitive and sample agnostic methods.

Funding Opportunity RFA-DA-26-018 from the NIH Guide for Grants and Contracts. Emerging threats continuously evolve. Xylazine, nitazenes, and other future threats are making their way or are already in the drug supply. Understanding them requires analyzing real world samples. Typically, testing strips are used to detect drug for which such strip exists, as the strips are fast, sensitive, low cost and reasonably accurate. However, as there might not be testing strips for the new threats, the analysis must be performed via sensitive and sample agnostic methods.

Notice NOT-OD-25-018 from the NIH Guide for Grants and Contracts

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

Competitive: BenevolentAI: We are looking for a talented Senior Bioinformatics Data Scientist to join the Product & Tech division. You will work in a cross-functional team apply London, United Kingdom

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

Competitive: King's College London: About Us The Sailem group is an interdisciplinary team dedicated to advancing deep learning and bioinformatics techniques for analysing large-scale London, United Kingdom

Notice NOT-MD-25-002 from the NIH Guide for Grants and Contracts

Notice NOT-GM-25-006 from the NIH Guide for Grants and Contracts

Notice NOT-AG-24-069 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-077 from the NIH Guide for Grants and Contracts. This announcement invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. Projects supported by this NOFO are expected to generate data that elucidate mechanisms of toxicity of these agents, possible new manifestations of toxic exposures, and potential new targets for therapeutic development.

Notice NOT-DC-25-006 from the NIH Guide for Grants and Contracts

Competitive: Medical Research Council: View Vacancy -- MRC Investigator Scientist in Bioinformatics and Genetics LMS 2509 Open Date 28/10/2024, 10:00 Close Date 20/11/2024, 23:55 R London, United Kingdom

£43,305 - £50,685: Barts Cancer Institute , Queen Mary University London: About the Role Applications are sought for a talented Bioinformatician to join the Centre for Tumour Microenvironment to provide and maintain the bio London, United Kingdom

Funding Opportunity PAR-25-143 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.All applications must be within the scope of the mission of one of the Institutes/Centers listed above.